Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
3.340
0.00 (0.00%)
At close: Nov 28, 2025, 1:00 PM EST
3.320
-0.020 (-0.60%)
After-hours: Nov 28, 2025, 4:22 PM EST
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$303,800
Profits / Employee
-$1,076,972
Market Cap
773.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 145 | 10 | 7.41% |
| Dec 31, 2023 | 135 | -43 | -24.16% |
| Dec 31, 2022 | 178 | -7 | -3.78% |
| Dec 31, 2021 | 185 | -11 | -5.61% |
| Dec 31, 2020 | 196 | 25 | 14.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GOSS News
- 5 days ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire
- 22 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 2 months ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 2 months ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 2 months ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 3 months ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire